The relationship between agonist binding to GPCRs and the conformational changes that facilitate G protein binding and activation remains largely unknown. Characterization of GPCR activation at a molecular level has been driven by a combination of X-ray crystal structure analysis and spectroscopic approaches. Rhodopsin has served as a prototype GPCR for biophysical studies, given its ready availability and superior stability. Crystal structures have been obtained for the inactive dark state with inverse agonist 11-*cis*-retinal covalently bound[@R4],[@R5], as well as the active state mimetic low-pH opsin lacking the retinal chromophore[@R6],[@R7]. Opsin differs from rhodopsin by outward rigid-body movements of transmembrane helices (TMs) 5 and 6 at the cytoplasmic G protein binding surface. For other GPCRs, which respond to diffusible ligands, structural information has proven more difficult to obtain. Fluorescence spectroscopy studies show that activation of the β~2~AR by diffusible ligands can follow multiple pathways, with a complex energy landscape of receptor conformations[@R8]. This multitude of accessible conformations has probably contributed to the difficulty in obtaining crystal structures of non-rhodopsin GPCRs.

Inactive state crystal structures of the β~2~AR, β~1~AR, and A~2A~ adenosine receptor have been solved over the past several years with the aid of protein engineering techniques[@R1], but agonist-bound structures for these proteins have yet to be reported. Like many GPCRs, the β~2~AR exhibits two agonist affinity states: a low affinity state in the absence of cognate G protein, and a high affinity state in the presence of G protein. This observation suggests that agonists can bind to two distinct receptor conformations. A more complete understanding of the processes of agonist binding and activation requires structures of both high and low affinity states. The high affinity state is challenging because a receptor-G protein complex is unstable in detergent solutions required for purification of both GPCRs and heterotrimeric G proteins. In a companion paper[@R3], we describe the use of a conformationally selective camelid antibody (nanobody, Nb80) with G protein-like properties to obtain a structure of a high-affinity agonist-bound conformation. Obtaining a structure of the low affinity state is also challenging because of the relatively rapid association and dissociation rates of commercial β~2~AR agonists. Inspired by the covalent retinal-rhodopsin system, we hypothesized that the ability to crystallize an agonist-bound GPCR would be enhanced by chemically crosslinking ligand and receptor, preferably in a manner that would not inhibit conformational freedom and the capacity to activate a G protein.

Our design strategy for a covalent β~2~AR agonist was to combine a β-adrenergic agonist core (procaterol) and a reactive chemical group that could be targeted to a specific residue on the receptor. Using the structure of the carazolol-bound β~2~AR as a template ([Figure 1A](#F1){ref-type="fig"}), a flexible linker was added to bridge these two components such that the covalent attachment would not inhibit binding of the agonist core or conformational flexibility of the transmembrane helices. Biochemical precedent for this strategy came from the covalent labeling reagent BABC ([Figure 1B](#F1){ref-type="fig"}), in which an electrophilic group appended to the carazolol ligand core was determined to react with His93^2.64^ at the extracellular end of TM2[@R9] (Ballesteros-Weinstein numbering[@R10] used in superscript). For crosslinking, we chose the reaction between a free cysteine on the receptor (introduced at position 93) and a ligand disulfide moiety, based on the mild and proximity-dependent "tethering" approach that has proven broadly applicable to different protein targets including GPCRs[@R11]. The designed covalent β agonist FAUC50 ([Figure 1B](#F1){ref-type="fig"}) was synthesized in enantiomerically pure form[@R12],[@R13], along with the noncovalent analog FAUC72 ([Figure 1B](#F1){ref-type="fig"}, [Figure S1, and Supplementary Information](#SD1){ref-type="supplementary-material"}) for use in control experiments.

Incubation of compound FAUC50 with mutant H93C receptor led to efficient and irreversible blocking of radioligand binding ([Figure S2, Supplementary Information](#SD1){ref-type="supplementary-material"}). We sought to determine whether the tethered FAUC50-β~2~AR^H93C^ complex is capable of activating a G protein. Wild-type and mutant receptor were reconstituted into High Density Lipoprotein (HDL) particles[@R14], and then incubated with ligand alone or ligand followed by an excess of the high-affinity inverse agonist ICI-118,551. Heterotrimeric G~s~ protein was then added to the particles, and activation was observed by measuring GTPγ^35^S binding to the G~s~α subunit. [Figure 1C](#F1){ref-type="fig"} shows that the inverse agonist treatment prevented agonist-induced G protein activation by the wild type receptor. However, excess ICI-118,551 is unable to reverse FAUC50-induced coupling in the case of β~2~AR^H93C^. The noncovalent analog FAUC72 is displaced by the inverse agonist for both wild type and H93C mutant receptors. From these experiments we conclude that FAUC50 not only reacts efficiently with Cys93 to form a covalent complex, but this complex is also capable of activating a G protein.

We were motivated to develop a covalent agonist by our inability to produce diffraction-quality crystals of the previously described β~2~AR-T4 lysozyme chimera (β~2~AR-T4L) in complex with available noncovalent agonists. In contrast, the purified FAUC50-β~2~AR^H93C^T4L complex readily yielded diffraction-quality crystals in lipidic mesophases[@R15]. We overexpressed the mutant receptor in Sf9 insect cells, purified the protein to homogeneity using immunoaffinity and ligand-affinity chromatography, and introduced the FAUC50 ligand during a subsequent chromatography step. Using a cholesterol-doped monoolein cubic phase and robotic *in meso* technology[@R16], we obtained 50×15×5 μm blade-shaped crystals ([Figure S3](#SD1){ref-type="supplementary-material"}) that diffracted to 3.5 Å. Combining diffraction data from 19 microcrystals ([Table S1](#SD1){ref-type="supplementary-material"}), we solved the agonist-bound structure by molecular replacement using the coordinates of carazolol-bound β~2~AR-T4L[@R17] as a search model. The packing of protomers in the orthorhombic crystals is distinct from previous crystals of β~2~AR-T4L fusion proteins. However, the orientation of T4L relative to the receptor closely resembles the original carazolol-bound structure (PDB ID 2RH1). An omit map at the ligand binding site reveals clear electron density for the agonist ([Figure S4](#SD1){ref-type="supplementary-material"}), and the refined structure shows prominent features expected from adrenergic receptor pharmacology[@R18]: the amine and β-hydroxyl of FAUC50 contact Asp113^3.32^ and Asn312^7.39^ in a manner similar to inverse agonists[@R17], while the aromatic moiety of FAUC50 that replaces the catechol ring forms hydrogen bonds with Ser203^5.42^ and Ser207^5.46^ ([Figure 2A](#F2){ref-type="fig"}, left).

The crystal structure of the covalent agonist-bound receptor in a lipidic mesophase does not show the conformational changes near the cytoplasmic surface associated with G protein binding, as observed in the nanobody-stabilized agonist complex ([Figure 2B](#F2){ref-type="fig"}). This was surprising given that the covalent agonist-bound receptor activates G~s~ ([Figure 1C](#F1){ref-type="fig"}) and the T4L fusion does not interfere with agonist-induced conformational changes detected with a fluorescent probe at the end of TM6[@R17]. This result implies that even an agonist with zero dissociation inefficiently stabilizes an active conformation of the β~2~AR in a lipid bilayer environment, consistent with a higher stability of the inactive carazolol-bound conformation. Nevertheless, allosteric communication between the ligand binding pocket and the cytoplasmic G protein binding surface is a fundamental feature of GPCRs, exemplified by agonist-induced G protein stimulation and G protein-induced high-affinity agonist binding [@R14]. For the β~2~AR, we can now compare an agonist-bound structure to that of a nanobody-stabilized active state mimetic (see companion paper[@R3]), to better understand conformational changes associated with activation. The superposition in [Figure 2B](#F2){ref-type="fig"} shows that agonist binding alone is insufficient to stabilize an active conformation at the cytoplasmic surface, with the requisite outward movement of TMs 5 and 6. The largest differences proximal to the ligand binding pocket in the nanobody-stabilized active conformation involve movement of Ile121^3.40^ away from Pro211^5.50^ and into space occupied by Phe282^6.44^ in the inactive state ([Figure 2C](#F2){ref-type="fig"}, middle). The concomitant outward movement of Phe282^6.44^ is accompanied by subtle backbone torsion changes distributed through TM6 that cause the cytoplasmic half of TM6 to be redirected outward, similar to its orientation in activated opsin[@R6],[@R7]. In the binding pocket, the most significant difference between the two agonist-bound structures and the carazolol-bound β~2~AR are in the hydrogen bonding contacts with Ser203^5.42^ and Ser207^5.46^ on TM5 ([Figure 2A](#F2){ref-type="fig"}). However, only in the nanobody-stabilized structure are these differences coordinated with further changes toward the cytoplasmic surface of the molecule ([Figure 2B and 2C](#F2){ref-type="fig"}, middle).

To determine whether an agonist-bound receptor would sustain a stable active conformation in the absence of a cytoplasmic binding partner, we initiated an unbiased molecular dynamics (MD) simulation of the receptor from the nanobody complex structure, but with the nanobody removed ([Figure 3A](#F3){ref-type="fig"}). In the first several microseconds of simulated time, the intracellular ends of TM5 and TM6 exhibited high mobility ([Figure S5](#SD1){ref-type="supplementary-material"}), drifting by as much as 5 Å from their crystallographic positions. After approximately 11 *μ*s, the agonist-bound receptor spontaneously transitioned to a more rigid conformation resembling the inactive, carazolol-bound structure and the covalent agonist-bound structure (superposition in [Figure 3B](#F3){ref-type="fig"}), which remained stable for the remainder of the 30-*μ*s simulation ([Figure 3A](#F3){ref-type="fig"}, top, and [Figure S6](#SD1){ref-type="supplementary-material"}). In particular, TMs 5 and 6 reverted to the positions they adopt in the inactive structure, as did a number of side chains, including Ile121^3.40^ and Phe282^6.44^ ([Figure 3A](#F3){ref-type="fig"}, bottom). Following the transition, the TM3--TM6 ionic lock was usually intact, as observed previously in simulations initiated from the inactive structure[@R19]. Although this 30-*μ*s simulation is an order of magnitude longer than any previously published atomistic simulation of a membrane protein, the transition to an inactive-like conformation took place more quickly than the millisecond timescales observed experimentally for adrenergic receptor activation[@R20]. An additional simulation with different protonation states for Asp79^2.50^ and Asp130^3.49^ ---two conserved residues whose protonation states have been suggested to change upon receptor activation [@R21],[@R22] ---exhibited similar behavior ([Figure S7](#SD1){ref-type="supplementary-material"}).

In the dynamic conformational equilibrium of a GPCR that links diffusible agonist binding and G protein association, the energies of different states reflect both the ligand binding energies and the conformations of the receptor and its binding partners. This can be depicted in a hypothetical energy landscape of the β~2~AR as shown in [Fig. 3C](#F3){ref-type="fig"}, where R, R′, R″ and R\* represent members of the ensemble of receptor conformations along an activation pathway. The constitutive activity displayed by the β~2~AR implies that the energy differences and barriers between inactive (R) and active (R\*) conformations are low enough to allow a significant population of active state receptors even in the absence of agonist. Agonist binding decreases the energy difference and thus increases the population of receptors in an active conformation; however, the inactive state is still the most stable conformation. Our crystallographic studies and MD simulations are compatible with fluorescence lifetime experiments on the purified receptor, demonstrating that saturating concentrations of a full agonist are incapable of pushing the β~2~AR conformational equilibrium toward a homogenous active state[@R23]. These results suggest that binding energy from a G protein or nanobody interaction is required to stabilize conformational changes such as those observed in the vicinity of Ile121^3.40^ and Phe282^6.44^ in the active state ([Figure 2C](#F2){ref-type="fig"}). Alternative biophysical approaches such as NMR[@R24],[@R25] and further molecular dynamics simulations will be crucial to fully understand these transitions and identify potential pathways and intermediates that are compatible with these structures.

METHODS SUMMARY {#S1}
===============

Synthetic chemistry methodology to generate FAUC50 and FAUC72 are described in [Supplementary Information](#SD1){ref-type="supplementary-material"}. Protocols for radioligand binding and G~s~ activation assays to characterize ligands, are described in Methods.

Crystallization {#S2}
---------------

FAUC50-β~2~AR^H93C^T4L was expressed, purified and crystallized as described in Methods. The receptor was crystallized in a cholesterol-doped (10%) monoolein cubic phase overlaid with precipitant in glass sandwich plates. Optimized precipitant consisted of 24--27 %(v/v) PEG400, 200 mM Li~2~SO~4~, 4 %(v/v) DMSO, 3.5 %(v/v) 1,4-butanediol, 100 mM MES pH 6.7. After 3--5 days of growth, crystals were harvested after adding an excess of precipitant solution for cryoprotection, and flash frozen in liquid nitrogen.

Data collection, structure solution and refinement {#S3}
--------------------------------------------------

Diffraction data were collected at beamline 23-ID (GM/CA-CAT) of the Advanced Photon Source, using a 10 μm diameter collimated microbeam. Oscillation data were measured in 1.0° frames with 10 sec or 25 sec exposures using 2x or 5x attenuated beam, respectively. The complete data set consisted of 106° of data from 19 crystals. The structure of FAUC50-β~2~AR^H93C^T4L was solved by molecular replacement, and refined by group B factor and TLS refinement. Full details are provided in Methods.

Molecular dynamics {#S4}
------------------

All-atom classical molecular dynamics simulations with explicitly represented lipids and water were performed using the CHARMM force field[@R26] on Anton[@R27], a special-purpose computer that accelerates such simulations by orders of magnitude; details are provided in the Methods.

METHODS {#S5}
=======

G protein activation assay with ICI-118,551 reversal {#S6}
----------------------------------------------------

Wild-type β~2~AR or β~2~AR^H93C^ were purified in unliganded form[@R28]. Samples of these receptors were reconstituted into rHDL particles as described[@R14]. For GTPγS binding assay, receptor-rHDL particles were pre-incubated with 5 μM FAUC50 or 5 μM FAUC72 for 4 hrs at 4 °C. Samples were diluted 20-fold into binding buffer and split. Half of the samples were used in GTPγS binding assays without ICI-118,551 competition, while the other half was incubated with 6 μM ICI-118,551 at room temperature for 1 hr with shaking. Control samples of receptor-rHDL particles with no ligand, 10 μM Isoproterenol, or 10 μM ICI-118,551 were also prepared. Purified Gs heterotrimer[@R29] was added to each sample and incubated for 10 minutes at 23 °C. The final concentrations of reconstituted receptor and Gs were 100 nM and 600 nM, respectively. GTPγS binding reactions were initiated by the addition of 0.4 nM \[^35^S\]GTPγS. Free \[^35^S\]GTPγS was removed by rapid filtration of the particles using glass fiber filters. Filter bound radioactivity was determined by liquid scintillation counting using a Beckman LS6000 scintillation counter. Data shown in [Figure 1C](#F1){ref-type="fig"} are from three independent experiments each performed in triplicate.

Purification of β~2~AR^H93C^T4L {#S7}
-------------------------------

The construct used for crystallography consisted of theβ~2~AR-T4L fusion protein[@R17] with the following modifications: a TEV site was inserted after residue 23 of the human β~2~AR sequence; Histidine 93 was mutated to cysteine; the construct was terminated by a 6xHis tag after residue 348 of human β~2~AR. This construct was cloned into the baculovirus transfer vector pVL1392, and the resulting vector was used to make a high-titer baculovirus stock using the Bestbac system (Expression Systems). The β~2~AR^H93C^T4L receptor was expressed in Sf9 insect cell cultures infected with this baculovirus, and Sf9 membranes were solubilized as described[@R17]. Purification was achieved using M1 FLAG affinity chromatography (Sigma), functional alprenolol-sepharose chromatography[@R30], and a second M1 chromatography concentrating step. While the receptor was still bound to the second M1 FLAG column, bound alprenolol was washed out and replaced with the covalent ligand using 3 hrs of washing with 15 column volumes of buffer containing 30 μM FAUC50 (10-fold total molar excess over receptor). Likewise, the dodecylmaltoside detergent used in all previous steps was exchanged for 0.1% (w/v) MNG-3 amphiphile [@R31]. Covalent agonist-bound and detergent-exchanged β2AR^H93C^T4L was eluted in \[20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% (w/v) MNG-3, 30 μM FAUC50\]. In contrast to previously published protocols, receptor was not alkylated prior to alprenolol-sepharose chromatography. Instead, receptor was alkylated after agonist exchange by treatment with 2 mM iodoacetamide for 30 minutes at 4 °C. Incubation of the eluate with AcTEV protease (Invitrogen) succeeded in removing the N-terminus of the receptor (23 amino acids plus TEV site, leaving a glycine scar preceding residue 24), as verified by SDS-PAGE analysis. The sample at this stage was further purified and concentrated using Ni chelating chromatography, taking advantage of the C-terminal 6xHis tag. Receptor was bound to a 0.7 ml column Ni-sepharose column, and eluted in \[20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% (w/v) MNG-3, and 30 μM FAUC50, 200 mM Imidazole\]. Finally, the receptor was concentrated to 50 mg/ml with a 100 kDa cutoff Vivaspin concentrator (Vivascience).

Crystallization {#S8}
---------------

Purified FAUC50-β~2~AR^H93C^T4L was crystallized using the *in meso* method[@R2]. Cubic phase reconstitution consisted of 2 parts 50 mg/ml receptor and 3 parts molten lipid mixture (10:1 monoolein:cholesterol by mass, lipids purchased from Sigma). Note that cholesterol is required for successful crystallization, and one cholesterol molecule is included in the refined model. Aqueous and lipid components were combined at room temperature using a syringe mixing apparatus[@R32]. Crystallization experiments in glass sandwich plates, set up by either by hand or using an *in meso* robot[@R16], consisted of 30--50 nL cubic phase overlaid with 800 nL precipitant. Precipitant conditions producing diffraction quality crystals were identified by screening around previous conditions[@R17], and testing additives and alternative buffers. Final optimized conditions consisted of 24--27 %(v/v) PEG400, 200 mM Li~2~SO~4~, 4 %(v/v) DMSO, 3.5 %(v/v) 1,4-butanediol, 100 mM MES pH 6.7. Crystals grew at 20 °C to a maximum size of 50 × 15 × 5 μm^3^ within 3 to 5 days (see [Figure S3, Supplementary Materials](#SD1){ref-type="supplementary-material"}). For harvesting and cryocooling, exposed crystallization drops were overlaid with an excess of precipitant solution, and cryoloops (MiTeGen) containing single crystals were flash frozen in liquid nitrogen.

Data collection and processing {#S9}
------------------------------

Diffraction data were collected at beamline 23-ID of the General Medicine and Cancer Institutes Collaborative Access Team (GM/CA-CAT) of the Advanced Photon Source, Argonne IL. All data was acquired using a 10 μm diameter collimated microbeam. Attenuated 1.0° rotation images were used to locate and center crystals within the opaque mesophase in each cryoloop. Oscillation data were measured in 1.0° frames with 10 sec or 25 sec exposures using 2x or 5x attenuated beam, respectively. Significant radiation damage caused decay in the signal that prevented merging more than the first 5--10° of oscillation data from each crystal. A total of 106° of data from 19 crystals were integrated with Mosflm[@R33] and merged with Scala[@R34].

Structure solution and refinement {#S10}
---------------------------------

Molecular replacement to obtain initial phases was performed with the program Phaser[@R35]. The separated structures of the receptor and T4L components of the high-resolution carazolol-bound β~2~AR structure (PDB ID 2RH1 with all non protein atoms removed), were used as search models. The model was refined in Phenix[@R36] and Buster[@R37], using group B factor refinement (one B factor per residue) followed by TLS refinement (using two TLS groups, one for the receptor and one for T4L). Refinement statistics are given in [Table S1 of Supplementary Information](#SD1){ref-type="supplementary-material"}. The crystallographic data was strongly anisotropic, as seen in the anisotropic B factor corrections, however the electron density was clear enough for the placement of side chains. While there was clear electron density present for the agonist (see omit map in [Figure S4, Supplementary Information](#SD1){ref-type="supplementary-material"}), we did observe a small discontinuity at the end of the linker connecting to Cys93. This discontinuity could arise from flexibility of the polymethylene component of the linker, as well as potential radiation damage[@R38] localized to the disulfide bond. As a control, we carried out refinement in which the ligand was modeled as a non-covalent species without a disulfide connection to the receptor. No significant differences in final model R/R~free~ or 2Fo-Fc and Fo-Fc electron density maps were observed.

Methods for molecular dynamics simulations {#S11}
------------------------------------------

In all simulations, *β*~2~AR was embedded in a hydrated lipid bilayer, with all atoms, including those in the lipids and water, represented explicitly. The BI-167107-bound *β*~2~AR simulations were initiated with the receptor and ligand in the conformation of the *β*~2~AR-NB80 crystal structure (companion paper), with the nanobody (NB80) removed. The carazolol-bound *β*~2~AR simulations were initiated with the receptor and ligand in the conformation of the high-resolution carazolol-bound crystal structure[@R17]. Both crystal structures were determined using a *β*~2~AR-T4L fusion protein, in which intracellular loop 3 (ICL3) of the receptor was replaced by T4 lysozyme (although the T4L was not resolved in the BI-167107-bound nanobody complex structure). We omitted the T4L in all simulations. Experimentally, removal of the bulk of ICL3 by partial tryptic digest does not appear to affect receptor function[@R37].

Production simulations were performed on Anton[@R27], a special-purpose computer designed to accelerate standard molecular dynamics simulations by orders of magnitude relative to the previous state of the art. Prior to production simulation, systems were equilibrated using Desmond[@R39] on a commodity cluster, according to the protocol described below.

### System setup and simulation protocol {#S12}

Hydrogens were added to the crystal structures of carazolol-bound *β*~2~AR (*β*~2~AR-Cz; PDB entry 2RH1) and *β*~2~AR-NB80/BI-167107 (companion paper) using Maestro (Schrödinger LLC, New York NY) as described previously[@R19]. T4L and NB80 were deleted, and chain termini were capped with neutral groups (acetyl and methylamino).

All titratable residues other than Glu122^3.41^, Asp79^2.50^, and Asp130^3.49^ were left in the dominant protonation state at pH 7.0. Glu122^3.41^ was protonated in all simulations. It faces the lipid bilayer and is thus likely protonated[@R40]; in addition, a similarly positioned residue in rhodopsin (Glu122^3.37^) has been found to be protonated during the entire photocycle[@R22].

We performed both BI-167107-bound and carazolol-bound simulations using two different sets of protonation states for Asp79^2.50^ and Asp130^3.49^. Previous studies have suggested that Asp130^3.49^ is protonated upon activation[@R22], and FTIR data has shown that this is the case for the corresponding residue of rhodopsin, Glu134^3.49-41^. Asp79^2.50^ is homologous to Asp83^2..50^ of rhodopsin, which has been found by FTIR spectroscopy to remain protonated during the entire photocycle[@R40]. On the other hand, neutralization of Asp79^2.50^ in *β*~2~AR by mutation to asparagine uncouples agonist binding from G protein activation [@R42], and a recent study suggested that Asp79 may be deprotonated upon activation[@R21]. Thus, we repeated each simulation with two sets of protonation states: first with Asp79 protonated and Asp130 deprotonated ("Ash79/Asp130," representing potential protonation states in the inactive receptor), and then with Asp79 deprotonated and Asp130 protonated ("Asp79/Ash130," representing possible protonation states in the active receptor). Results shown in [Figures 3](#F3){ref-type="fig"}, [S5, and S6](#SD1){ref-type="supplementary-material"} are for the Ash79/Asp130 simulations, while results in [Figure S7](#SD1){ref-type="supplementary-material"} are for the Asp79/Ash130 simulations.

*β*~2~AR residues that were truncated or not resolved in the crystal structures were omitted from the simulations. In particular, N-terminal residues 1--28, C-terminal residues 343--413, and ICL3 residues 231--262 were omitted from the carazolol-bound system, while N-terminal residues 1--22, C-terminal residues 345--413, and ICL3 residues 228--265 were omitted from the BI-167107-bound system. Both simulations included a glutamate at position 187, reflecting an Asn187Glu mutation made in both crystallization constructs to eliminate a glycosylation site.

We prepared the carazolol-bound Ash79/Asp130 *β*~2~AR system following our previously described protocol[@R19], and the other systems according to an updated protocol (details below). We do not expect the differences in the simulation setup protocols to affect the quantities of interest in this study. As a control, however, we performed an additional 5 *μ*s simulation of a carazolol-bound Ash79/Asp130 *β*~2~AR system prepared according to the new protocol and obtained results (not shown) similar to those of the 15 *μ*s carazolol-bound Ash79/Asp130 *β*~2~AR simulation prepared according to the old protocol

Prepared protein structures were inserted into an equilibrated phospholipid bilayer solvated with 0.15 M NaCl as described previously[@R19]. Carazolol-bound Ash79/Asp130 *β*~2~AR was simulated in a POPE bilayer system initially measuring 85 × 73 × 88 Å^3^, containing 170 lipid molecules, 8,798 water molecules, 19 sodium ions, and 24 chloride ions, for a total of 52,396 atoms. Carazolol-bound Asp79/Ash130 *β*~2~AR was simulated in a POPC bilayer system initially measuring 83 × 83 × 87 Å^3^, containing 160 lipid molecules, 11,313 water molecules, 30 sodium ions, and 35 chloride ions, for a total of 60,153 atoms. (The 5 *μ*s carazolol-bound Ash79/Asp130 control simulation prepared according to the new protocol also used a POPC bilayer.) BI-167107-bound *β*~2~AR (both Ash79/Asp130 and Asp79/Ash130) was simulated in a POPC bilayer system initially measuring 79 × 79 × 87 Å^3^, containing 138 lipid molecules, 10,116 water molecules, 26 sodium ions, and 31 chloride ions, for a total of 53,603 atoms.

All systems were equilibrated in the NPT ensemble at 310 K and 1 bar using the Berendsen coupling scheme with 5 kcal mol^−1^ Å^−2^ harmonic position restraints applied to all non-hydrogen atoms of the protein; these restraints were tapered off linearly over 5 ns. Unrestrained systems were then simulated for an additional 5 ns to further equilibrate the aspect ratio of the simulation box. During the equilibration process, Van der Waals and short-range electrostatic interactions were cut off at 9 Å for the carazolol-bound Ash79/Asp130 *β*~2~AR system and at 12 Å for the other systems. Long-range electrostatic interactions were computed using the Particle Mesh Ewald method[@R43], with a 64 × 64 × 64 grid and *σ* = 2.26 Å for the carazolol-bound Ash79/Asp130 *β*~2~AR system, and with a 32 × 32 × 32 grid and *σ* = 3.23 Å for the other systems; fifth-order B-splines were used for interpolation in both cases. All bond lengths to hydrogen atoms were constrained using M-SHAKE[@R44]. A RESPA integrator[@R45] was used with a timestep of 2 fs, and long-range electrostatics were computed every 6 fs.

Production simulations on Anton were initiated from the final snapshot of each corresponding equilibration runs on Desmond, using the same integration schemes. Van der Waals and short-range electrostatic interactions were cut off at 9 Å for the carazolol-bound Ash79/Asp130 *β*~2~AR system and at 13.5 Å for the other systems. Long-range electrostatics were computed using the *k*-space Gaussian Split Ewald method[@R46], with a 64 × 64 × 64 grid, *σ* = 2.01 Å, and *σ*~s~ = 1.41 Å for the carazolol-bound Ash79/Asp130 *β*~2~AR system, and with a 32 × 32 × 32 grid, *σ* = 3.33 Å, and *σ*~s~ = 2.35 Å for the other systems.

### Force field parameters {#S13}

The CHARMM27[@R26] parameter set (with CMAP terms[@R47]) and the CHARMM TIP3P[@R48] water model were used for all protein molecules, POPE lipid molecules, water molecules, and salt ions. A modified CHARMM lipid force field[@R49], which became available after we performed the 15-*μ*s simulation of carazolol-bound *β*~2~AR in POPE, was used for POPC lipids. Force field parameters for carazolol and palmitoyl-cysteine were designed previously[@R19]. Force field parameters for BI-167107 were transferred from previously parameterized model compounds: parameters for the hydroxyethylamine "tail" group were transferred from the alkylamine parameters we previously designed for carazolol[@R19], and parameters for the benzoxazine "head" group were transferred from the model compounds anisole and *p-*phenol acetamide from the CHARMM General Force Field[@R50]. Full parameter sets are available upon request.

### Analysis protocols {#S14}

Trajectory snapshots, each containing a record of all atom positions at a particular instant in time, were saved every 180 ps during production simulation. Distance and RMSD measurements were computed using the HiMach parallel analysis framework[@R51].

The distance and RMSD measurements shown in [Figures 3A](#F3){ref-type="fig"}, [S5, and S7](#SD1){ref-type="supplementary-material"} are smoothed; the smoothed time series were computed from the original time series by a weighted running average, using a filter kernel of half-width 12.51 ns whose shape corresponded to that of the cosine function from −*π*/2 to *π*/2.

VMD[@R52] was used to visualize trajectories and to produce the molecular renderings of [Figure 3B](#F3){ref-type="fig"}.
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![Design and function of a covalent agonist\
**a,** Structure of the carazolol-bound β~2~AR, receptor in gray cartoon and ligand in yellow sticks, showing distance between isopropyl group and His93^2.64^ imidazole. **b**, Structures of carazolol and the related BABC ligand, covalent ligand FAUC50 and noncovalent analog FAUC72. **c**, G protein activation assay demonstrating that covalently bound FAUC50 activates the β~2~AR.](nihms252051f1){#F1}

![Comparison of agonist bound β~2~AR structures\
Comparison of the covalent FAUC50-bound β~2~AR^H93C^T4L (left panels, blue cartoon, ligand carbons in purple), BI-167107-bound β~2~AR-T4L/nanobody (β~2~AR-Nb80) complex (middle panels, orange cartoon, ligand carbons in green), and carazolol-bound β~2~AR-T4L (right panels, cyan cartoon, ligand carbons in yellow). **a**, Hormone binding site with interactions between ligands and receptors. TMs 6 and 7 with residues Phe289, Asn293, and Try308 are omitted for clarity. **b**, Comparison of the cytoplasmic surfaces showing differences in TMs 5 and 6. Superimposed β~2~AR-Nb80 complex is also shown in left panel as a transparent cartoon, and arrows indicate rigid body movements. **c**, Conformational switch region with residues Ile121^3.40^, Pro211^5.50^, and Phe282^6.44^ from TMs 3, 5, and 6 (other TMs transparent). Sidechains are shown in van der Waals sphere representation. A dashed line is shown at an equivalent position in each receptor.](nihms252051f2){#F2}

![Molecular dynamics simulations\
**a,** An unbiased simulation initiated from the nanobody complex (β~2~AR-Nb80) structure, with the agonist BI-167107 bound but the nanobody removed (magenta), and a carazolol-bound simulation initiated from the inactive structure (β~2~AR-Cz) (blue). (top) Distance between C~α~ atoms of Arg131^3.50^ and Leu272^6.34^, and (bottom) RMSD of non-symmetric non-hydrogen atoms in residues Ile121^3.40^ and Phe282^6.44^. Dashed lines indicate corresponding quantities from crystal structures. **b**, Cytoplasmic view of the simulated agonist-bound receptor after 30 μs, compared to the β~2~AR-Nb80 (left) and β~2~AR-FAUC50 (right) structures. The conformations of intracellular loop 2, Tyr219^5.58^, and Glu268^6.30^ shown for the agonist-bound simulation differ from β~2~AR-FAUC50, but have been observed in inactiveβ~2~AR simulations[@R19] and in other inactive-state GPCR structures[@R1]. **c**, Proposed energy landscape model, in which both an agonist and a cytoplasmic binding partner are required to stabilize the fully active receptor conformation \[R\*\] over intermediate \[R′ and R″\] and inactive \[R\] states.](nihms252051f3){#F3}
